Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)

Launched by UNIVERSITY HOSPITAL SCHLESWIG-HOLSTEIN · Mar 31, 2025

Keywords

ClinConnect Summary

The HYPOSTAT-III trial is studying a type of treatment for localized prostate cancer called hypofractionated radiosurgery. This method typically involves delivering radiation in five smaller doses over time. However, this trial is investigating whether giving the treatment in just three smaller doses is safe and effective. Researchers want to see if this approach results in fewer side effects, particularly issues related to the urinary and gastrointestinal systems, after one year.

To be eligible for this trial, participants must be adult males aged 18 or older with confirmed localized prostate cancer that meets certain criteria, such as a specific cancer grade and prostate size. Participants will need to provide written consent and must not have had previous pelvic radiation or certain other medical conditions that could interfere with the study. While the trial is not yet recruiting, it aims to offer insights into potentially improving treatment for localized prostate cancer with fewer side effects. If you or someone you know is considering this option, it could be a chance to contribute to important research in cancer care.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Localised, histopathologically confirmed Prostate Cancer (cT1-T2c N0 M0)
• • Gleason-grade ≤7, ISUP Grade Group 1-3
• • Guideline-based staging
• • Age ≥ 18 years
• • PSA \< 20 ng/ml
• • Volume of the prostate \< 80 cm³
• • IPSS-Score ≤ 12
• • Written informed consent
• Exclusion Criteria:
• • History of prior pelvic radiotherapy
• • Previous transurethral resection, laser enucleation or prostate ablation
• • Contraindication to MRI or Fiducial marker implantation (e.g. gold allergy)
• • Relevant comorbidity thought to adversely affect treatment compliance
• • Legal incapacity or lack of informed consent